Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: A French national study of raltegravir-experienced HIV-1-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1507-1512

  Fourati, Slim ^a   Charpentier, Charlotte ^b,c,d   Amiel, Corinne ^e   Morand Joubert, Laurence ^f   Reigadas, Sandrine ^g   Trabaud, Mary Anne ^h   Delaugerre, Constance ⁱ   Nicot, Florence ^j   Rodallec, Audrey ^k   Maillard, Anne ^l   Mirand, Audrey ^m   Jeulin, Hélène ⁿ   Montès, Brigitte ^o   Barin, Francis ^p   Bettinger, Dominique ^q   Le Guillou Guillemette, Hélène ^r   Vallet, Sophie ^s   Signori Schmuck, Anne ^t   Descamps, Diane ^b,c,d   Calvez, Vincent ^a   Flandre, Philippe ^a   Marcelin, Anne Genevieve ^a   Lagier, E ^u   Roussel, C ^u   Le Guillou, H ^u   Alloui, C ^v   Bettinger, D ^u   Pallier, C ^u   Fleury, H ^u   Reigadas, S ^u   Bellecave, P ^u   Recordon Pinson, P ^u   Payan, C ^u   Vallet, S ^u   Vabret, A ^u   Henquell, C ^u   Mirand, A ^u   Bouvier Alias, M ^u   de Rougemont, A ^u   Dos Santos, G ^u   Morand, P ^u   Signori Schmuck, A ^u   Bocket, L ^u   Rogez, S ^u   Andre, P ^u   Tardy, J C ^u   Trabaud, M A ^u   Tamalet, C ^u   Delamare, C ^u   Montes, B ^u   Schvoerer, E ^u   Ferre, V ^u   Andre Garnier E ^u   Cottalorda, J ^u   Guinard, J ^u   Guiguon, A ^u   Descamps, D ^d   Brun Vezinet F ^d   Charpentier, C ^d   Visseaux, B ^d   Peytavin, G ^d   Krivine, A ^w   Si Mohamed, A ^x   Avettand Fenoel, V ^y   Marcelin, A G ^z   Calvez, V ^z   Lambert Niclot, S ^z   Soulie C ^z   Wirden, M ^z   Morand Joubert, L ^aa   Delaugerre, C ^ab   Chaix, M L ^ab   Amiel, C ^ac   Schneider, V ^ac   Giraudeau, G ^u   Brodard, V ^u   Maillard, A ^u   Plantier, J C ^u   Chaplain, C ^u   Bourlet, T ^u   Fafi Kremer, S ^u   Stoll Keller, F ^u   Schmitt, M P ^u   Barth, H ^u   Yerly, S ^ad   Poggi, C ^u   Izopet, J ^u   Raymond, S ^u   Barin, F ^u   Chaillon, A ^u   Marque Juillet, S ^u   Roque Afonso, A M ^u   Haim Boukobza S ^u   Flandre, P ^ae   Grude M ^ae   Assoumou, L ^ae   Costagliola, D ^ae   more..

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h CROIX ROUSSE HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j CHU PURPAN   (France)

^k NANTES UNIVERSITY HOSPITAL   (France)

^l RENNES UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ UNIVERSITY HOSPITAL OF NANCY   (France)

^o HÔPITAL SAINT ELOI   (France)

^p UNIVERSITY HOSPITAL OF TOURS   (France)

^q HÔPITAL SAINT JACQUES   (France)

^r ANGERS UNIVERSITY HOSPITAL   (France)

^s SERVICE DE RHUMATOLOGIE   (France)

^t GRENOBLE UNIVERSITY HOSPITAL   (France)

^u HEGP ^*  (France)

^v Necker ^*  (Tunisia)

^w Institut Cochin   (France)

^x HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^y Necker Institute   (France)

^z PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^aa Saint Antoine University   (France)

^ab Saint Louis Institute Paris Diderot   (France)

^ac Tenon   (France)

^ad Institut Suisse   (Switzerland)

^ae INSERM   (France)

more..

Author keywords

Inhibitors; Integrase; Mutations; Patterns

Indexed keywords

ABACAVIR; DARUNAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTEGRASE; MUTANT PROTEIN; QUINOLONE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE;

ADULT; ARTICLE; CROSS RESISTANCE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); VIRUS LOAD; VIRUS MUTATION; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; FRANCE; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; FRANCE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTANT PROTEINS; QUINOLONES; RALTEGRAVIR POTASSIUM; SEQUENCE ANALYSIS, DNA;

EID: 84929755856     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku535     Document Type: Article

References (24)

1. Rockstroh JK, DeJesus E, Lennox JL et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013; 63: 77-85.
2. Eron JJ, Cooper DA, Steigbigel RT et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013; 13: 587-96.
3. Kobayashi M, Yoshinaga T, Seki T et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21.
4. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. New Engl J Med 2008; 359: 355-65.
5. Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52: 1351-8.
6. Delelis O, Thierry S, Subra F et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 2010; 54: 491-501.
7. Goethals O, Clayton R, Van Ginderen M et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82: 10366-74.
8. Eron JJ, Clotet B, Durant J et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207: 740-8.
9. Castagna A, Maggiolo F, Penco G et al. Dolutegravir in antiretroviralexperienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210: 354-62.
10. Descamps D, Delaugerre C, Masquelier B et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78: 153-60.
11. Hurt CB, Sebastian J, Hicks CB et al. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2014; 58: 423-31.
12. Hare S, Smith SJ, Metifiot M et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011; 80: 565-72.
13. Min S, Song I, Borland J et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54: 254-8.
14. Quashie PK, Mesplede T, Han YS et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705.
15. Mesplede T, Osman N,Wares M et al. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 2014; 69: 2733-40.
16. Wainberg M, Anstett K, Mesplede T et al. The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. J Int AIDS Soc 2014; 17 Suppl 3: 19518.
17. Mesplede T, Quashie PK, Osman N et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013; 10: 22.
18. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8.
19. Malet I, Fourati S, Charpentier C et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 2011; 66: 2827-30.
20. Malet I, Gimferrer Arriaga L, Artese A et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother 2014; 69: 2118-22.
21. Raffi F, Jaeger H, Quiros-Roldan E et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, noninferiority trial. Lancet Infect Dis 2013; 13: 927-35.
22. Malet I, Fourati S, Morand-Joubert L et al. Risk factors for raltegravir resistance development in clinical practice. J Antimicrob Chemother 2012; 67: 2494-500.
23. Dolling D, Nelson M, Schwenk A et al. Rapid increase in the frequency of wild-type HIV-1 drug resistance reports among ART-experienced patients in the UK. In: Abstracts of the Twentieth Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Abstract 594. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
24. Briz V, Garrido C, Poveda E et al. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses 2009; 25: 225-7.